Medicare AdvantageCoverageMedium impact
MA06.013e, Serodiagnosis of Inflammatory Bowel Disease (IBD) and the Prometheus® IBD sgi Diagnostic™ Test
Independence Blue Cross·Gastroenterology, Internal Medicine, Family Medicine·Pharmacy
Effective date
Jun 10, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA06.013e regarding serodiagnosis of Inflammatory Bowel Disease (IBD) and the Prometheus IBD sgi Diagnostic Test has been reissued. This is a pharmacy category policy update that will take effect June 10, 2026.
Action Required
By June 10, 2026: Review updated policy MA06.013e for IBD serodiagnosis and Prometheus IBD sgi Diagnostic Test requirements. Billing team should access the full policy details at the source URL to understand any changes to coverage criteria, prior authorization requirements, or documentation needs for IBD diagnostic testing under Medicare Advantage plans.